<DOC>
	<DOCNO>NCT03067909</DOCNO>
	<brief_summary>Hundreds thousand patient undergo implantation replacement cardiac implantable electronic device ( CIEDs ) annually Europe , 50 % subject receive antiplatelet agent oral anticoagulant . Antithrombotic therapy increase risk develop pocket hematoma turn associate increase risk potentially fatal device-related infection clinically significant . Aim registry retrospectively ( pilot local registry Tuscany ) prospectively ( multicenter national registry Italy ) investigate different strategy management antithrombotic therapy relate complication rate ( 1-month 12-months ) patient undergo CIED surgery real-world setting . The registry also provide data economic impact different management strategy complication .</brief_summary>
	<brief_title>Antithrombotic Therapy Patients Undergoing CIED Surgery - HEMATOMA NO MORE Registry</brief_title>
	<detailed_description />
	<mesh_term>Hematoma</mesh_term>
	<mesh_term>Arrhythmias , Cardiac</mesh_term>
	<mesh_term>Prosthesis-Related Infections</mesh_term>
	<criteria>Patients standard indication CIED surgery treat antiplatelet agent and/or anticoagulant ( commercially available device approve marketed drug include ) . Patients able provide write informed consent Patients willing attend plan followup visit Patient life expectancy le 12 month per investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>